A novel, NH2-terminal sequence-characterized human monokine possessing neutrophil chemotactic, skin-reactive, and granulocytosis-promoting activity by unknown
-TERMINAL SEQUENCE-CHARACTERIZED
ONOKINE POSSESSING NEUTROPHIL
CHEMOTACTIC, SKIN-REACTIVE, AND
GRANULOCYTOSIS-PROMOTING ACTIVITY
By JO VAN DAMME,* JOZEF VAN BEEUMEN,t GHISLAIN OPDENAKKER,* AND
ALFONS BILLIAU*
From the *Rega Institutefor Medical Research, University ofLeuven, B-3000 Leuven, Belgium;
and the CLaboratory ofMicrobiology, Faculty of Sciences, State University of Ghent, B-9000
Ghent, Belgium
locytes is an important element of
the acute local inflammatory response. It is brought about by adherence ofneu-
trophils to the endothelial linings of small blood vessels, followed by movement
through the vessel wall and into the inflamed tissue. These phenomena are
known to involve the action of membrane-bound receptors, as well as soluble
chemotactic factors. Some of these factors are chemotactic per se, while others
act by changing the expression of membrane-associated molecules involved in
adhesion.
Chemotactic agents that play a role in the inflammatory reaction may be exog-
enous (e.g., of bacterial origin) or endogenous (reviewed in reference 1). The
classical example of an endogenous factor is the plasma-derived, activated com-
plement factor C5a. Other endogenous chemotactic factors are those released
locally by any of the cells that take part in inflammation: endothelial cells, plate-
lets, monocytes, lymphocytes, or granulocytes themselves. Examples ofsuch cell-
released chemotactic agents are leukotriene B4 (LTB4)' and platelet-activating
factor (PAF). Certain cytokines, e.g., IL-1, have also been described to possess
chemotactic activity (2).
We here describe the biological and biochemical characterization of a human
macrophage-derived factor that, in vitro, possesses chemotactic activity for gran-
ulocytes and, in vivo, induces granulocytosis upon systemic injection and skin
reaction upon local injection in experimental animals. The kinetics of appear-
ance of the in vivo effects suggest that this factor is a mediator for similar effects
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induced by IL-l . The factor was purified to homogeneity and its N112-terminal
sequence was determined. The sequence was found to correspond to that
deduced from a cDNA sequence "3-1OC" coding for a protein that has itself
not been isolated, to which no biological activity could as yet be assigned, but
that has sequence homology with the platelet factors ,B-thromboglobulin (8TG)
and platelet factor 4 (PF4).
Materials and Methods
Production of Chemotactic Factor and &TG.
￿
Human peripheral blood leukocytes were
isolated and fractionated from pooled buffy coats provided by the Blood Transfusion
Centers of Leuven and Antwerp (Belgian Red Cross). Red blood cells were removed by
sedimentation (30 min) in hydroxyethyl starch (PlasmasterilR; Fresenius AG, Bad Hom-
burg, Federal Republic of Germany). Platelets were separated by centrifugation at low
speed (300 g, 10 min). Mononuclear cells were isolated by gradient centrifugation (400
g, 30 min) on Ficoll-sodium metrizoate (Lymphoprep; Nyegaard, Oslo, Norway). Cells
were suspended at 5 X 106 cells/ml in RPMI 1640 (Gibco, Paisley, Scotland) supple-
mented with 2% FCS using spinner flasks. The adhering cell population was obtained by
incubating the mononuclear cell fraction in stationary cultures for 2 h at 37°C. Non-
adherent cells were then removed by repeated washes and the cultures were replenished
with Eagle's minimum essential medium (EMEM) supplemented with 2% FCS. The adher-
ent cell fraction consisted of 80% monocytes as tested microscopically using phycoery-
thrine-conjugated human Leu-M3 antibody (Becton Dickinson & Co., Mountain View,
CA).
Suspended platelets, free of leukocytes, were stimulated at 37°C with thrombin
(Topostasine, Hoffmann-La Roche, Basel, Switzerland) at 1 U/ml for 2 h or were left
untreated for 24 h. Total mononuclear cell suspension and adhering cell fractions were
stimulated for 48 h at 37°C with Con A (Calbiochem-Behring Corp., San Diego, CA) or
LPS from Fscherichia coli (0111 : B4; Difco Laboratories, Detroit, MI).
Purification ofChemotactic Factor and,BTG.
￿
Crude supernatants from stimulated mono-
nuclear cells, adhering cells, or platelets were concentrated and partially purified by
adsorption to silicic acid (Mallinckrodt Inc., Paris, KY) and elution with 50% ethylene
glycol containing PBS at pH 7.4 as described previously (3). The second purification step
consisted of adsorption of impurities to DEAE-Sephacel (Pharmacia Fine Chemicals,
Uppsala, Sweden) in 20 mM Tris-HCl buffer, pH 7.5. The DEAE-Sephacel-unadsorbed
fraction was concentrated by dialysis against 20 mM Tris-HCl buffer, pH 7.5, containing
15% polyethylene glycol 20,000 (Serva, Heidelberg, Federal Republic of Germany) and
further fractionated by gel filtration on Ultrogel AcA 54 (LKB Produkter, Bromma, Swe-
den) using a 2 .6 cm (inner diameter) X 100 cm column equilibrated with 18% ethylene
glycol in 1 .55 M NaCI, 8 mM phosphate, pH 7 .2.
The 15-30-kD fractions from gel filtration were then concentrated and purified by
fast protein liquid chromatography (FPLC). The material was applied to a Mono S cation
exchange column (Pharmacia Fine Chemicals, Uppsala, Sweden) in 50 mM formate
buffer, pH 4.0. Biological activity was eluted at a flow rate of 1 ml/min with a linear
NaCl gradient (0-0.65 M), followed by a step-wise gradient to I M NaCl.
SDS-PAGE was done as described by Laemmli (4). Samples were loaded onto linear
gradient (8-30% wt/vol) polyacrylamide gels containing 0.1% (wt/vol) SDS with a 5%
stacking gel containing 0.25% SDS. The gels (17 X 13 X 0.1 cm) were stained with
Coomassie blue. The molecular weight markers (Bio-Rad Laboratories, Richmond, CA)
used were phosphorylase b (M, 92,500), BSA (Mr 66,200), OVA (M, 45,000), carbonic
anhydrase (M, 31,000), soybean trypsin inhibitor (Mr 21,500), lysozyme (M, 14,400) and
the low molecular mass markers (Pierce Chemical Co., Rockford, IL), cytochrome c (M,
12,500), and aprotinin (Mr 6,500).
Induction of Skin Reactivity and Granulocytosis In Vivo.
￿
Skin reactivity was measured in
triplicate in New Zealand White rabbits. Rabbits were shaved at the abdomen and1366
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injected subcutaneously with 150 A1 of FPLC column fractions (12 samples per rabbit),
concentrated, and dialyzed against PBS + 15% polyethylene glycol. Skin reactivity was
measured with 3-h time intervals by measuring the diameter of the swelling and the
intensity of coloring. The reaction was scored arbitrarily but twice independently at each
time interval. Scores for the different rabbits were averaged and expressed as a percent-
age of maximal skin reactivity (1 .5-cm diameter of redness) as obtained with a concen-
trated standard preparation of partially purified (FPLC input) material.
Induction of granulocytosis was measured in rabbits (^- 3 kg) by intravenous injection
(3 ml) of different doses of the test material, verified for purity by SDS-PAGE, and
dialyzed against pyrogen-free saline. Blood samples (1 ml) were collected in heparinized
tubes at several time intervals after treatment by bleeding at a peripheral ear vein. Total
leukocytes were counted in duplicate using a hemacytometer. The percentage of granu-
locytes was determined in duplicate by 100-cell differential cell counts of a smear stained
with Wright-Giemsa solution. Control rabbits injected with pyrogen-free physiological
saline showed during the 30-h test period a <25-% change in total or differential cell
counts as compared with the average cell number (n = 3) before injection. Average
changes in cell counts of >50% of the cell number before treatment must thereby be
considered as significant.
In Vitro Assay for Granulocyte Chemotaxis.
￿
Populations of polymorphonuclear neutro-
phils and mononuclear cells were separated by gradient centrifugation (30 min, 400 g)
of heparinized human peripheral blood from a single donor on Ficoll-sodium metrizoate.
The pellet, containing granulocytes and erythrocytes, was suspended in hydroxyethyl
starch for 30 min to remove erythrocytes by sedimentation. Residual erythrocytes were
eliminated by lysis in bidistilled water (30 s). Purified neutrophils were finally obtained
by centrifugation (30 min, 20,000 g) in a Percoll gradient (d = 1 .054). Granulo-
cytes were washed, counted, and resuspended at 2 X 107 cells/ml in HBSS (Gibco), sup-
plemented with pyrogen-free human plasma protein (1 mg/ml albumin, Cohn fraction
V) .
Chemotaxis was measured under agarose as described by Nelson et al. (5). In each
agarose dish, six series of three wells (2.8-mm diameter) were cut. The center well of
each series received 10 u1 of the purified granulocyte population (2 X 105 cells/well) .
The inner and outer wells were filled with 10 11 of test sample and control nonchemo-
tactic medium (HBSS -f- albumin), respectively. FMLP (Sigma Chemical Co., St. Louis,
MO) at 10-7 M was used as a positive control chemotactic factor in each dish . After
incubation (37°C, 5% COO for 2-3 h maximal chemotaxis could be observed in the
FMLP+ control. At that time cells were fixed with methanol and formaldehyde (37%) .
Test samples were scored microscopically for chemotactic activity by measuring the
migration distance of the cells. Quantification for effective migration was calculated from
the actual migration distance (toward the chemotactic factor) by subtraction of the spon-
taneous migration distance (toward the negative control medium). For each sample at
least three dilutions were tested in duplicate. The titration endpoint corresponding to 1
U/ml was calculated from the dilution resulting in half-maximal effective migration dis-
tance as compared with that obtained with FMLP (10 - ' M). Titers for chemotactic activ-
ity were expressed in logo U/ml.
Determination of ,B-TG.
￿
The concentrations of (3TG in fractions obtained by FPLC
were determined with a commercially available radioimmunoassay kit (Amersham Inter-
national, Buckinghamshire, UK). Since the standard solutions present in this kit were
ranging from 10 to 225 ng/ml, column fractions containing ,#TG at the microgram level
were appropriately prediluted (in bidistilled water) to obtain a final concentration
between 20 and 150 ng/ml. Interference in the assay by other compounds present in the
column fractions was not likely, in view of the high purification rate achieved at the
FPLC stage.
IL-1 Assay.
￿
IL-1 activity was measured by its antiviral effect against vesicular stoma-
titis virus on human MG-63 osteosarcoma cells as described (6), 1 U/ml of IL-1 corre-
sponding to half-maximal protection of the test cells against the virus. The titers for II.-
I (loglo U/ml) as obtained by this method correspond to those obtained in the murinethymocyte costimulatory assay. The preparation and biological determination of other
natural cytokines is described in (6).
NH2-terminal Amino Acid Sequence Analysis.
￿
NH2-terminal amino acid sequence anal-
out on a gas-phase sequencer (Model 470A; Applied Biosystems, Inc.,
Foster City, CA) with off-line identification of the PTH-amino acids by HPLC on a 4.6
X 250 min IBM cyanopropyl column (7). Methanolic HCl was used as reagent to convert
the thiazolinones so that the PTH derivatives of Asp, Glu, and carboxymethylcysteine
were automatically methylated. The latter compound was identified following the pro-
tocol described in (8).
Results
Isolation of a Skin-reactive Factor Differentfrom IL-1.
￿
IL-1Q produced by mito-
gen-stimulated leukocytes was purified by consecutive adsorption to silicic acid,
DEAE-Sephacel, and gel filtration as described (3, 9) . The 15-30-kD fractions
from gel filtration, containing all IL-I (22 kD) activity, were then pooled and
separated on a cation-exchange FPLC column at pH 4.0. Frac
dialyzed against PBS were tested for in vitro and in vivo biological effects of IL-
1 . Antiviral activity on fibroblasts (6) was taken as an in vitro test for IL-1 while
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FIGURE 1 .
￿
Separation of skin-reac-
tive factor different from IL-1 by
cation exchange chromatography.
Fractions (150 Eel) of mitogen-stimu-
lated leukocyte supernatants puri-
fied by FPLC (Mono S, pH 4.0)
were injected subcutaneously and
skin reactivity was registered after 3
h and 24 h. IL-1 was detected in the
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skin reactivit
detection. Fig. 1 shows that on FPLC all antiviral activity eluted in a single peak
at 0.3 7 M NaCl. Concordantly, a late (24 h) skin reactivity consisting of redness
and swelling was observed with this antivirally active fraction. SDS-PAGE of such
peak fraction revealed a single protein of 17,000 kD identifiable as IL-1,6 by
NHz-terminal sequence analysis (9).
In addition to the late skin reactivity, as observed with IL-10, an early (3 h)
but persisting reaction in rabbits was seen with a fraction eluting at I M NaCl,
but containing no antiviral (11- 1) activity (Fig. 1). Such reaction consisted of a
swelling and red coloring of ^- I cm in diameter. The nature of this biologically
active component and its relation to IL-1 were further investigated.
Chemotactic Activity In Vitro with Fractions Inducing Skin Reactivity.
Pathological examination of skin biopsies from rabbits in which skin reactions
were induced revealed strong neutrophil granulocyte infiltration . This led us to
test whether skin reactivity containing fractions from FPLC were chemotactic
for granulocytes in vitro (Table 1) . Several cytokine preparations were used as
controls, including pure natural IL-10 (from FPLC), IFN-0, and IL-6 (10), as
well as the inducer substances Con A and LPS. As shown in Table 1, none of
TABLE I
Chemotaetic Activity ofFPLC Fractions Inducing Early Skin. Reactivity
* Skin reactivity at 4h aftersubcutaneous injection in rabbits of 150,1/fraction (values
are averages of three independent scores); a crude cytokine preparation was used as
positive control (FPLCinput material).
Expressed as endpoint dilution resulting
pared with EMIT,
alf-maximal mi distance as com-
Batch number
or substance
Fraction number
or dose
Earlyskin reaction*
(percent of control)
Chemotactic activity
(end pointdilution)
42029 Input 100 ND
49-50 <10 ND
51-52 <10 ND
53-54 72 ND
55-56 <10 ND
57-58 <10 ND
43053 51 <10 <1/3
52 <10 <1/3
53 77 1/250
54 11 1/25
55 <10 <1/3
80 51 ND <1/3
52 ND <1/3
53 ND 1/400
54 ND 1/100
55 N1) 1/6
IL-10 2,000 U/ml <10 <I/3
IFN-13 10,000 U/ml ND <1/3
IL-6 10,000 U/ml ND <1/3
LPS 1,000 ng/ml ND <1/3
Con A 1,000 ng/ml ND <1/3VAN DAMME ET AL .
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FIGURE 2 . SDS-PAGE of purified chemotactic
factor .A linear gradient gel wasrun with 10 u1 (C)
of FPLC fraction no . 53 (20 Ag/ml) under reduc-
ing conditions and stained with Coomassie blue .
M, markers (X 10-3) are shown (A and B) .
these control substances scored positive in this assay for chemotaxis . In contrast,
FPLC fractions from mitogen-stimulated leukocyte supernatants showing the
early skin reaction did stimulate in vitro chemotaxis (Table I) indicating that they
contained a factor different from the controls . It can further be seen that the
peaks of chemotactic activity and skin reactivity coincided with FPLC fraction
No . 53 . SDS-PAGE of such peak fraction revealed a single protein band of M,
6,500, indicating that both the in vitro and in vivo activities reflected the effect
of the same molecule (Fig. 2) . Confirmation for this was obtained by an exper-
iment in which an FPLC fraction No . 53 was run on a gel under nonreducing
conditions, followed by slicing of the gel and detection of biological activity in
the eluates from each slice . This experiment demonstrated that the biological
activity fully coincided with the 6.5-kD protein band .
NHZ-Terminal Amino Acid Sequence of the Chemotactic Factor.
￿
Since the che-
motactic factor was found to copurify with IL-1, the different purification steps
were verified in respect of the yield of activity recovered . Although the chemo-
tactic assay might detect several related factors, it was noticed that ^-50% (n =
8) of the biological activity could be recovered after the first two purification
steps (adsorption to silicic acid and DEAE-Sephacel) . It was verified that most
of the chemotactic activity indeed coeluted with IL-1 upon subsequent gel fil-
tration at a higherM r (15-30 X 103) than 6.5 X 103, suggesting that this mol-
ecule could occur as a multimer . Finally, no loss of chemotactic activity was
observed (n = 5) during cation exchange FPLC .
Several preparations from FPLC (about 40 Ag each), tested for purity by SDS-
PAGE and for chemotactic activity, were sequenced in a gas-phase sequenator.
One of these preparations was carboxymethylated before sequence analysis in
order to detect cysteine residues . For the different runs a single and identical1370
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NH2-terminal protein sequence was obtained which reads:
The sequence showed strong homology with that of the human platelet factors
#TG (11) and PF-4 (12). Moreover, complete identity was observed with a
cDNA-derived sequence (3-10C) that in its entirety codes for a protein (M,
11,000) of 99 amino acid residues (13). Since this cDNA has so far not been
expressed and tested for biological activity, it is not known which activity, if any,
the corresponding protein may have. The location of the NH2-terminus of the
naturally produced chemotactic factor isolated in our laboratory is different
from that of the amino acid sequence inferred from the 3-10C cDNA on the
basis of hydrophobicity analysis. In addition, the molecular mass of our che-
motactic factor is significantly lower than that postulated for the 3-1OC putative
protein. A weak homology was also seen with another human cDNA-derived
sequence (14) coding for a protein called -YIP-10.
Cell Source for Human Chemotactic Factor.
￿
Since the platelet factor $TG,
related to the isolated chemotactic factor, was also detected in partially purified
preparations from mitogen-stimulated leukocytes, it was investigated which cell
types were the producers of these molecules in our system. Different cell frac-
tions were isolated, cultured, and stimulated. The supernatants were purified
following the same procedure as that used for supernatants of unfractionated
leukocytes. It can be seen from Fig. 3 (left) that, with FPLC as a final purification
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Determination of chemotactic activity and S'I'G in FPLC fractions of superna-
tants from stimulated platelets (Iefl) and monocytes (right). Supernatants were purified and
tested for activity as described in Materials and Methods. Histograms are indicating chemo-
tactic activity (-) and OTG (-----) respectively. The FPLC column was subjected to a
linear NaCl gradient (----) and the absorbance was monitored at 280 mri (-).
15step, OTC, produced from platelets eluted at a position different from that of
the chemotactic factor from unfractionated cells. In addition, platelets did not
produce this chemotactic activity. It was further found that the chemotactic fac-
tor was not released by the granulocyte fraction, but was produced by mono-
nuclear cells. It was then shown (Fig. 3, right) that Con A- or LPS-stimulated
adherent cells were potent producers of the chemotactic factor, while no il3TG
activity was released by those cells. This is in agreement with the finding of oth-
ers that the mRNA that corresponds to the protein occurs in the histiocytic lym-
phoma cell line U937 (13). It thus appears that the chemotactic protein and
#TG, although structurally related, are produced by different cell types.
Human Chemotactic Factor Induces Granulocytosis In Vivo. Although IL-1,Q
failed to act chemotactically in vitro, it is known to exert a profound in vivo
influence on leukocyte counts. Our studies in this regard (9, 15) revealed that
the effect of IL-1(3 was biphasic, in that an immediate granulopenia was followed
by a later granulocytosis. As demonstrated by Fig. 1, both the chemotactic factor
and IL-1# induce skin reactivity, although with different kinetics. To further
investigate the role of this chemotactic factor for granulocyte physiology and its
possible role in the hematological effects of IL-1, pure factor was injected intra-
venously into rabbits (Fig. 4). It was observed that the chemotactic factor rapidly
induced a profound granulocytosis (up to fourfold increase in circulating gran-
ulocyte numbers) . This granulocytosis peaked at 1/2 to 2 h after injection and
normal cell counts could be restored within 8 h. This effect was found to be
dose dependent, 100 U/kg of in vitro chemotactic activity being the minimum
effective in vivo dose. The fast granulocytosis as induced by the chemotactic fac-
E
0
k
m
16
VAN DAMME ET AL.
￿
1371
T
￿
i
￿
m
￿
e
￿
l hours )
FIGURE 4.
￿
Effect of human chemotactic factor on circulating granulocyte counts. Rabbits
were injected intravenously with 50 I1 (--0---), 100 jl (--0--), and 200 Al (-o-), respectively
of FPLC-purified chemotactic factor (50 ug/ml). Peripheral blood cell counts and control
rabbits were as described in Materials and Methods.1372
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for suggests that the delayed granulocytosis promoting effect of IL-10 could be
mediated by this factor. This would also explain the delayed (24 h) skin reactivity
with IL-10 as compared with the early effect (3 h) with the chemotactic factor,
as well as the lack of chemotactic activity of IL-1/3 in vitro (Table 1). With respect
to the effect of the chemotactic factor on the number of circulating mononu-
clear cells, no significant changes were observed even at the highest dose (400
U/kg) tested. This is also in contrast with IL-10, which showed lymphopenia
upon intravenous injection in rabbits (9, 15).
Since LPS is known to possess an effect on circulating granulocytes similar to
that of IL-1, contamination of the pure chemotactic factor with LPS had to be
excluded. First it was observed that surrounding fractions from FPLC contain-
ing no IL-1(3 nor chemotactic factor had no significant effect (<25% increase
or decrease) on granulocyte counts, excluding LPS contamination coming from
the column. Second, peak fractions of chemotactic factor from FPLC contained
only low amounts of endotoxin (< 150 pg/ml as tested in a Limulus amoebocyte
lysate assay), corresponding to a maximal injected dose of <30 pg per rabbit.
Such low doses of LPS (E. coli) could not explain the effect on granulocyte
counts in rabbits, since doses of LPS as high as 30 ng per rabbit did not have
such an effect (data not shown) . Third, LPS-induced hematological effects (300
ng/rabbit) have a different pattern in that an early (2 h) granulopenia is fol-
lowed by granulocytosis (10 h). Finally, peak fractions of chemotactic factor did
not provoke fever upon injection in rabbits, whereas LPS (100 ng/rabbit) was
indeed pyrogenic (data not shown) .
Discussion
Macrophage-derived factors such as IL-1 and TNF have been found to play
an important role in host reactions against infection, cancer, allergens, and
autoantigens. Numerous biological in vivo effects, including induction of fever,
acute-phase reactants, and neutrophilia, have been attributed to these factors
(16) . However, in vitro studies have demonstrated that several of these activities
are in fact indirect, i.e., mediated by other factors induced by IL-1 or TNF.
Thus it is well known that IL-1-induced thymocyte activation is mediated by
induction of IL-2. Similarly, as evident from our work, IL-1 has IFN-like (6, 9)
and colony-stimulating factor (9, 17) activities which can be explained by induc-
tion of the corresponding cytokines. The finding that IL-1 is a potent inducer
(10) of IL-6, a growth factor for B cells (IL-6 or HGF) and a stimulating factor
for hepatocytes (IL-6 or HSF) (18), suggests that the B cell-stimulating effect
of IL-1 and its ability to induce acute-phase proteins are mediated by this mol-
ecule. Induction of neutrophilia by 11:1 is not paralled by in vitro effects on
granulocytes (19, 20), again suggesting intervention of a mediator.
One of the in vivo reactions possibly to be attributed to macrophage-derived
factors is the elicitation of skin inflammation, an activity first described as skin-
reactive factors, present in supernatants of mitogen-stimulated leukocytes (21).
While studying the possible role of IL-1 (9) in the causation of such skin reac-
tions, we discovered and purified a 6.5-kD protein distinct from IL-1 that could
induce skin reaction at an earlier time than IL-1 . Such acute inflammatory
lesions have also been shown to be induced by a number of exogenous agents,VAN DAMME ET AL.
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including Con A and LPS (22). However, in contrast to those agents as well as
the cytokines IL-1, IFN-,Q, and IL-6, this 6.5-kD factor possessed in vitro che-
motactic activity for granulocytes. These in vitro findings confirm the lack of
chemotactic activity of IL-1 as described by others (19, 20). Furthermore, we
found that our newly isolated chemotactic factor could induce an immediate and
dose-dependent granulocytosis in vivo, while, as evident from our previous work
(9, 15), IL-1f induced a more delayed neutrophilia. These differences between
IL-1(3 and the chemotactic factor with respect to kinetics of both skin reactivity
and neutrophilia, together with the absence of an in vitro chemotactic effect of
IL-1 suggest that these in vivo effects of IL-1 are mediated by this or related
chemotactic factor(s). Direct evidence for such inducer hypothesis was provided
by demonstration of chemotactic activity in monocyte cultures treated with IL-
1. However, unstimulated adherent cell populations also produced a significant
amount of chemotactic activity. Whether this activity is mediated by a sponta-
neous release of IL-1 from the monocytes is presentlybeing investigated. Similar
observations were done on monocytes with respect to the production of IL-6
after treatment with IL-1 .
The possibility that the observed biological effects were due to contaminating
endotoxin was excluded by several observations: (a) inability of LPS to induce
in vitro chemotaxis of granulocytes; (b) absence of significant amounts of LPS
(as tested by the Limulus amoebocyte lysate assay) sufficient to induce granulo-
cytosis; and (c) lack of pyrogenicity of purified factor in rabbits.
The chromatographical procedure used to isolate this chemotactic factor was
that originally developed for purification of IL-I . Nevertheless, it was observed
that as much as 50% of the chemotactic activity present in the crude material
was recovered after the final purification step. However, we have recently been
able to purify this molecule to homogeneity by a more efficient sequence of
purification steps, including adsorption to silicic acid, heparin-Sepharose chro-
matography, and FPLC (manuscript in preparation).
Evidence for a single protein being responsible for the observed activities was
obtained by SDS-PAGE analysis of the FPLC-purified factor, showing a protein
band of Mr 6,500 coeluting with the chemotactic activity. NH2-terminal amino
acid sequence analysis identified the protein as being different from all chemo-
tactic factors known so far. However, this stretch of sequence was identical with
that derived from the nucleotide sequence of a cDNA clone (3-10C) isolated
from mitogen-stimulated human leukocytes (13). In addition, some 50% homol-
ogy was also observed with the low Mr platelet factors #TG and PF-4 (11, 12) to
which some chemotactic activity has been ascribed (23). We could verify that
monocytes but not platelets were the producer cells of this novel chemotactic
protein. Furthermore, platelet-derived OTG was found to be separable from the
chemotactic factor by cation exchange chromatography. Purified #TG failed to
exert significant chemotactic activity on granulocytes at concentrations up to 10
,,g/ml. In contrast, pure chemotactic factor showed a much higher specific activ-
ity (^-105 U/mg). It can therefore be concluded that the observed in vitro and
in vivo effects are reflecting the physiological role of this novel molecule. The
6.5-kD factor also showed homology with an IFN-y-inducible cytokine (-YIP-1 0).
Although the yIP-10 gene codes for a predicted protein of 10 kD (14), it has1374
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recently been shown that, due to posttranslational processing, the mature pro-
tein also has an Mr of 6-7 X 103 (24). A similar posttranslational modification
could explain the difference in Mr between our chemotactic factor (6 .5 X 103)
and that of the protein predicted from the identical 3-1 Oc sequence (11 X 10).
In addition, biological similarity between our factor and the 'YIP-10 protein
exists in that both are involved in skin reactivity (25) .
It will be of interest to determine whether the chemotactic factor also exerts
some of the other biological properties ascribed to the platelet factors OTG and
PF-4, such as affinity for heparin (26), immunoregulatory activity (27), histamine
release from basophils (28), stimulation of leukocyte elastase (29), inhibition of
PGI2 production in endothelial cells (30), chemotaxis for fibroblasts (31). It will
also be important to further clarify the relation between this new neutrophil-
chemotactic factor and other agents that have been described to possess similar
activities but that are still not fully characterized (19, 32-35) .
Summary
A factor able to induce an early local inflammation in rabbit skin was detected
in the supernatant of mitogen-stimulated human blood leukocytes. The factor
was different from IL-I which, although present in the supernatants, was chem-
ically separable from the factor and induced a late rather than an early skin
response .
Other biological effects of the principal factor were its in vitro chemotactic
effects on granulocytes and its ability to induce rapid granulocytosis upon intra-
venous injection in rabbits. When tested under the same conditions, IL-1,Q did
not act chemotactically and induced granulocytosis at a later time.
The factor was purified to homogeneity and identified by electrophoretic
mobility as a protein of Mr 6,500. Amino acid sequence analysis revealed the
presence of an uncontaminated NH2-terminal sequence identical to a segment
of the sequence previously predicted (13) from the cDNA clone (3-1OC) copied
from an mRNA isolated from human leukocytes and coding for a protein of
unknown function. The N112-terminal sequence of the factor also showed exten-
sive homology to that of the platelet factors ,0-thromboglobulin (QTG) and plate-
let factor 4 (PF-4). Studies done to identify the cell source of the factor revealed
that it was produced by adherent mononuclear cells but not by platelets, while
the opposite was true for OTG.
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